{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:27:21Z","timestamp":1791584841103,"version":"4.3.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Polycystic ovary syndrome (PCOS) is a heterogeneous endocrinological and metabolic disorder which is the common cause of female infertility. The dysmetabolism displayed in it has not been completely ascertained. Metabonomics may shed light on understanding many small molecule endogenous metabolites and their associated metabolic pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyze the different metabolites and related metabolic pathways in follicular fluid and embryo culture fluid of PCOS and non-PCOS groups. Finding markers predictable for clinical outcomes of <jats:italic>in vitro<\/jats:italic> fertilization-embryo transfer (IVF-ET) treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Population and sample<\/jats:title><jats:p>60 women who underwent IVF-ET were selected, including 30 with PCOS and 30 with the fallopian tubal issues only. We collected the first tube follicular fluid (FF) of all patients at the time of oocyte pick up and the waste embryo culture medium (ECM) after D3 high-quality embryo transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All samples were performed nontargeted Ultra High Performance Liquid Chromatography-Mass Spectrometry (UHPLC-QE-MS) analysis. Related metabolic pathways were screened by KEGG annotation. To search potential indicators, the logistic regression was made combined with clinical data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Mean outcome measures<\/jats:title><jats:p>Predictive performance of\u00a0markers of clinical outcomes (pregnancy rate, delivery rate, live birth rate, miscarriage rate) of assisted reproductive technology (ART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Comparing the PCOS group against the non-PCOS group, we found 11 significantly different metabolites in the FF and 56 in the ECM. There are a total of 11 kinds of biomarkers associated with clinical outcomes. Androsterone sulfate, Glycerophosphocholine, and Elaidic carnitine seem robust to predict the abortion rate of the PCOS group, with an AUC of 0.941, 0.933, 0.933, respectively. The glycerol phospholipid metabolic pathway is enriched in both the follicular fluid and embryo culture fluid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The differential metabolites were mainly a variety of lipids. Some of them can predict clinical outcomes to a certain extent.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.982200","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T04:30:52Z","timestamp":1662093052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Potential biomarkers for clinical outcomes of IVF cycles in women with\/without PCOS: Searching with metabolomics"],"prefix":"10.3389","volume":"13","author":[{"given":"Shang-yue","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-xia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2963","article-title":"Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome","volume":"102","author":"Gibson-Helm","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094715","article-title":"Metabolomics: a global biochemical approach to drug response and disease","volume":"48","author":"Kaddurah-Daouk","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod50.2.225","article-title":"Ovarian follicular growth and development in mammals","volume":"50","author":"Fortune","year":"1994","journal-title":"Biol Reprod"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.theriogenology.2007.04.007","article-title":"Metabolomics: approaches to assessing oocyte and embryo quality","author":"Singh","year":"2007","journal-title":"Theriogenology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.03.078","article-title":"Noninvasive metabolomic profiling as an adjunct to morphology for noninvasive embryo assessment in women undergoing single embryo transfer","volume":"94","author":"Seli","year":"2010","journal-title":"Fertil Steril"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-019-2055-x","article-title":"Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: Comparison of clinical outcomes and ovarian response","volume":"39","author":"Xiao","year":"2019","journal-title":"Curr Med Sci"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1201\/b14680","article-title":"A textbook of in vitro fertilization and assisted reproduction: The bourn hall guide to clinical and laboratory Practice1992","author":"Brinsden","year":"2005"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-5-946","article-title":"Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome","volume":"61","author":"Wild","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/humupd\/dmq032","article-title":"Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence","volume":"17","author":"Qiao","year":"2011","journal-title":"Hum Reprod Update"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2005.12.009","article-title":"Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects","volume":"39","author":"Garg","year":"2006","journal-title":"Clin Biochem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.freeradbiomed.2015.05.013","article-title":"Metabolism alteration in follicular niche: The nexus among intermediary metabolism, mitochondrial function, and classic polycystic ovary syndrome","volume":"86","author":"Zhao","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(86)80281-5","article-title":"Enhanced lipid utilization in infants receiving oral l-carnitine during long-term parenteral nutrition","volume":"109","author":"Helms","year":"1986","journal-title":"J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mrd.23104","article-title":"Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry","volume":"86","author":"Jia","year":"2019","journal-title":"Mol Reprod Dev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2006.06.007","article-title":"Risk assessment for carnitine","volume":"46","author":"Hathcock","year":"2006","journal-title":"Regul Toxicol Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/den109","article-title":"Serum total l-carnitine levels in non-obese women with polycystic ovary syndrome","volume":"23","author":"Fenkci","year":"2008","journal-title":"Hum Reprod"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.11.016","article-title":"Metabolic alterations associated with polycystic ovary syndrome: A UPLC q-exactive based metabolomic study","volume":"502","author":"Chen","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/61609","article-title":"L-carnitine treatment of insulin resistance: A systematic review and meta-analysis","volume":"26","author":"Xu","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbrep.2016.11.010","article-title":"Carnitine acetyltransferase: A new player in skeletal muscle insulin resistance","volume":"9","author":"Berg","year":"2017","journal-title":"Biochem Biophys Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-020518-114455","article-title":"Branched chain amino acids","volume":"81","author":"Neinast","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80re2","DOI":"10.1126\/scitranslmed.3002043","article-title":"Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss","volume":"3","author":"Laferr\u00e8re","year":"2011","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00134.2007","article-title":"Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism","volume":"293","author":"She","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/104542","article-title":"Branched chain amino acids: Passive biomarkers or the key to the pathogenesis of cardiometabolic diseases","volume":"28","author":"Siomkaj\u0142o","year":"2019","journal-title":"Adv Clin Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12958-019-0490-y","article-title":"Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry","volume":"17","author":"Sun","year":"2019","journal-title":"Reprod Biol Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23393","article-title":"Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome","volume":"9","author":"Jov\u00e9","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1194\/jlr.R046094","article-title":"Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells","volume":"55","author":"Hishikawa","year":"2014","journal-title":"J Lipid Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biophys.093008.131234","article-title":"The distribution and function of phosphatidylserine in cellular membranes","volume":"39","author":"Leventis","year":"2010","journal-title":"Annu Rev Biophys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1021\/pr500145n","article-title":"Lipidomics reveals a link between CYP1B1 and SCD1 in promoting obesity","volume":"13","author":"Li","year":"2014","journal-title":"J Proteome Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M014787","article-title":"Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance","volume":"52","author":"Han","year":"2011","journal-title":"J Lipid Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.024869","article-title":"Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes","volume":"284","author":"Yea","year":"2009","journal-title":"J Biol Chem"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.982200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T04:30:56Z","timestamp":1662093056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.982200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":30,"alternative-id":["10.3389\/fendo.2022.982200"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.982200","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"982200"}}